ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Arcutis Biotherapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZORYVE foam | $229.44M | $201.28M | $181.89M | $150.37M | $120.85M | $95.24M | $71.54M | $40.41M | $20.14M | $6.54M | $0 | – | 49.5% | +89.9% |
| ZORYVE cream 0.3% | $137.93M | $130.28M | $121.00M | $112.31M | $103.86M | $93.44M | $85.08M | – | – | – | $29.19M | – | 29.7% | +32.8% |
| ZORYVE cream 0.15% | $89.41M | $79.80M | $68.27M | $51.25M | $34.76M | $20.14M | $9.92M | $2.45M | $0 | – | $0 | – | 19.3% | +157.2% |
| Product revenue, net | – | – | – | – | – | – | – | – | – | – | $29.19M | $3.69M | – | – |
| Other revenue | – | – | – | – | – | – | – | – | – | – | $30.42M | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Arcutis Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.